Intellia Therapeutics' NTLA-2002 Shows Promise With Potential Stock Surge
Intellia Therapeutics, Inc. (NTLA) the Most Promising Biotech Stock According to Hedge Funds?
BMO Capital Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $70
Express News | Intellia Therapeutics Inc : Leerink Partners Cuts Target Price to $60 From $68
Intellia Therapeutics Announces New Date for Upcoming Investor Webcast
Intellia Therapeutics Inc (NTLA) Q2 2024 Earnings Call Highlights: Strategic Advances and ...